Back to top
more

Annovis Bio (ANVS)

(Delayed Data from NYSE)

$7.69 USD

7.69
323,906

-0.56 (-6.79%)

Updated Aug 9, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

by Zacks Equity Research

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

by Zacks Equity Research

Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

by Zacks Equity Research

Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.

Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues

by Zacks Equity Research

Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.

Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.

Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates

by Zacks Equity Research

Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.

GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review

by Zacks Equity Research

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

by Zacks Equity Research

Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

by Zacks Equity Research

Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

by Zacks Equity Research

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists

by Zacks Equity Research

Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.

uniQure (QURE) Soars on New Huntington's Disease Study Data

by Zacks Equity Research

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

by Zacks Equity Research

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

by Zacks Equity Research

Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

by Zacks Equity Research

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

by Zacks Equity Research

Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.